Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 2 records in total 2
    records per page




    Initial experience in Mexico with convalescent plasma in COVID-19 MESHD patients with severe respiratory failure, a retrospective case series

    Authors: Michel F. Martinez-Resendez; Fernando Castilleja-Leal; Alejandro Torres-Quintanilla; Augusto Rojas-Martinez; Gerardo Garcia-Rivas; Rocio Ortiz-Lopez; Victor Trevino; Reynaldo Lara-Medrano; Hiram Villanueva-Lozano; Teresa Ramirez-Elizondo; Victor Sanchez-Nava; Francisco Moreno-Hoyos; Alfonso Martinez-Thomae; Martin Hernandez-Torre; Carlos Diaz-Olachea; Servando Cardona-Huerta; Sylvia de la Rosa-Pacheco; Carlos Diaz-Garza; Paola Reynoso-Lobo; Alma R. Marroquin-Escamilla; Jessica G. Herrera-Gamboa; Fatima M. Alvarado-Monroy; Claudia D. Aguayo-Millan; Francisco F. Villegas-Macedo; Jesus E. Flores-Osorio; Daniel Davila-Gonzalez; Maria E. Diaz-Sanchez; Guillermo Torre-Amione

    doi:10.1101/2020.07.14.20144469 Date: 2020-07-20 Source: medRxiv

    Introduction: Hospital mortality due to COVID-19 MESHD in Mexico is high (32%) and as of today, effective treatment options are limited. More effective treatments that shorten hospital stay and reduce mortality are needed. Initial reports for the use of convalescent plasma (CP) therapy for COVID-19 MESHD appear promising. We describe a case series of eight patients with impending respiratory failure MESHD, who underwent CP therapy. Methods: Six male and two female (ages 31 to 79) patients that were admitted to the intensive-care unit for severe COVID-19 MESHD were transfused with two doses of CP (250 mL per dose, anti-SARS-CoV-2 IgG titers > 1:100). Donors were six SARS-CoV-2 infected MESHD males who remained asymptomatic for > 7 days and were negative for two nasopharyngeal RT-PCR tests. Clinical characteristics, inflammatory and cellular injury markers, chest X-ray findings and viral loads were analyzed before and after CP administration. Viral load association to disease severity was further analyzed on a separate cohort of asymptomatic vs hospitalized patients with COVID-19 MESHD. Results: Eight patients with respiratory failure MESHD were successfully discharged with a median length of stay of 22.5 (IQR 18.25-29.00). After CP therapy, we observed a reduction of C-reactive protein HGNC ( CRP HGNC) (median, 22.80 mg/dL vs. 1.63 mg/dL), and of procalcitonin (median, 0.27 ng/mL vs. 0.13 ng/mL). High-Sensitivity Cardiac Troponin I (hs- cTnI HGNC), Brain Natriuretic Peptide ( BNP HGNC) and Lactate Dehydrogenase (LDH) were lower, and a mild reduction of pulmonary infiltrates by chest X-ray was observed. Lastly, a reduction of viral load was after CP therapy was found. (log, median [IQR], 1.2 [0.70-2.20] vs. 0.25 [0.00-1.78]). We observed no adverse effects. Conclusions: CP could potentially be an effective therapeutic option for patients with severe COVID-19 MESHD. Clinical benefit needs to be studied further through randomized controlled trials.

    Baseline echocardiographic assessment of left ventricle kinetics alteration and mortality risk in a cohort of critically ill COVID-19 MESHD patients

    Authors: Davide Ceccato; Beatrice Gusella; Mattia Grassi; Alessandro Toffolon; Anna Postal; Davide Gorgi; Federico Capone; Alois Saller; Alberto Cipriani; Cristiano Sarais; Roberto Vettor; Raffaele Pesavento

    doi:10.21203/rs.3.rs-35798/v1 Date: 2020-06-15 Source: ResearchSquare

    Background SARS-CoV2 infection MESHD are frequently associated with cardiovascular manifestations, in particular with symptomatic acute coronary syndromes MESHD, cardiac arrhythmias MESHD and acute heart failure MESHD. However, the elevation of serum troponin seems to be non specific, and a cardiologic diagnostic workup should be performed. We aimed to assess the clinical characteristic and the prevalence of left ventricular (LV) dyssynergy patterns MESHD in a cohort of hospitalized non-critically ill COVID-19 MESHD patientsMethods Consecutive patients with an objective diagnosis of COVID-19 MESHD, from February to April 2020. Baseline characteristics and comorbidities was collected. In case of increased troponin levels or symptoms suggestive for a concomitant cardiac syndrome MESHD, patients undergo to serial electrocardiograms, serial Troponin tests and bedside transthoracic echocardiogram.Results 402 consecutive patients were enrolled: 55 patients underwent an echocardiographic exam because of an increase in troponin levels or a suspected myocardial injury MESHD. Segmental left ventricular abnormalities MESHD were found in 10 (median WMSI 2.03 IQR 1.38-2.75) with a median LV MESHD ejection fraction was 30.1 % IQR, median troponin level was 3083 ng/L, median BNP HGNC was 761 ng/L. Death for any cause occurred in 4 patients among patients with regional LV abnormalities MESHD and in 3 with normal regional function (p= 0,02).Discussion A single bedside transthoracic echocardiogram performed in non critically ill COVID-19 MESHD patients with suspected cardiac injury MESHD has the potential to better assist clinicians in their challenging decision process. As an isolated increase of troponin levels is common in COVID patients, a bed-side echocardiographic evaluation of cardiac function should be routinely implemented during their early evaluation.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.